HM15211



NAME OF DRUG : HM15211

ALSO KNOWN AS : HM15211

LABORATORY : HanmiPharmaceutical

STATUS AND ADVANCEMENT

Type of drug : long-acting GLP-1, GIP and glucagon triple agonist

Clinical trials advancement : Recruiting Phase 1

Estimated time to market : 134 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON HM15211

SOME PUBLICATIONS RELATED WITH HM15211

October 2018 : Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in NASH and fibrosis animal models

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH HM15211


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE